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Abstract 39 
Introduction: Volatile organic compounds (VOCs) in breath can reflect host and pathogen metabolism 40 
and might be used to diagnose pneumonia. We hypothesized that rats with Streptococcus pneumoniae 41 
(SP) or Pseudomonas aeruginosa (PA) pneumonia can be discriminated from uninfected controls by 42 
thermal desorption – gas chromatography – mass-spectrometry (TD-GC-MS) and selected ion flow tube – 43 
mass spectrometry (SIFT-MS) of exhaled breath.  44 
Methods: Male adult rats (n=50) received an intra-tracheal inoculation of 1) 200 µL saline, 2) 1x107 45 
colony forming units (CFU) of SP or 3) 1x107 CFU of PA. 24 hours later the rats were anaesthetized, 46 
tracheotomized and mechanically ventilated. Exhaled breath was analyzed via TD-GC-MS and SIFT-MS. 47 
Area under the receiver operating characteristic curves (AUROCCs) and correct classification rate (CCRs) 48 
were calculated after leave-one-out cross-validation of sparse partial least squares-discriminant analysis 49 
(sPLS-DA).  50 
Results: Analysis of GC-MS data showed an AUROCC (95% CI) of 0.85 (0.73 – 0.96) and CCR of 94.6% for 51 
infected vs. non-infected animals, AUROCC 0.98 (0.94 – 1) and CCR of 99.9% for SP vs. PA, 0.92 (0.83 – 52 
1.00) and CCR of 98.1% for SP vs. controls and 0.97 (0.92 – 1.00) and CCR of 99.9%for PA vs. controls. For 53 
these comparisons the SIFT-MS data showed AUROCCs of 0.54, 0.89, 0.63 and 0.79, respectively. 54 
Discussion: Exhaled breath analysis discriminated between respiratory infection and no infection, but 55 
with even better accuracy between specific pathogens. Future clinical studies should not only focus on 56 
the presence of respiratory infection, but also on the discrimination between specific pathogens.57 
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Introduction 58 
Exhaled breath analysis of volatile organic compounds (VOCs) represents a promising new technique for 59 
diagnosing respiratory infection (12, 20, 24). Our recent review(19), however, has shown that current 60 
studies using breath analysis did not show sufficient diagnostic accuracy and lack consistency to be used 61 
for pneumonia in mechanically ventilated intensive care unit (ICU) patients.  62 
Studies investigating individual infection related VOCs or VOC patterns in human breath 63 
encounter certain challenges, such as: 1) all possible pathogens are investigated at once; 2) for 64 
pneumonia no gold standard is available(13); and 3) due to co-existing factors such as comorbidities, 65 
drugs, and diet, it might be difficult to determine the biochemical origin of VOCs. The application of 66 
exhaled breath metabolomics or breathomics is rapidly expanding(6, 18). Specific VOC profiles for certain 67 
bacterial strains can be identified(5).  In vitro studies using bacterial cultures(16, 17) do not take into 68 
account the host response, and bacteria appear to grow differently in culture media compared to living 69 
lung tissue(8).   70 
To date animal studies investigating VOCs for diagnosis of pneumonia(1, 28, 29) primarily used 71 
secondary electrospray ionization - mass spectrometry (SESI-MS) as analytical platform for breath 72 
analysis, resulting in breathprint patterns associated with certain microorganisms. However, 73 
identification of  specific individual VOCs is preferable, since this could guide future human studies. 74 
Capture of breath on suitable sorbent tubes followed by thermal desorption into gas chromatography-75 
mass spectrometry (TD-GC-MS) can identify individual VOCs and is currently seen as the gold standard 76 
regarding exhaled breath analysis(8). Selected ion flow tube – mass spectrometry (SIFT-MS) offers the 77 
possibility of on-line breath analysis, and thus might enable future application for exhaled breath 78 
monitoring at the patient’s bedside.   79 
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Within the scope of this study exhaled breath in a rat pneumonia model was investigated, for 80 
two common causative pathogens of pneumonia: Streptococcus pneumoniae (SP) and Pseudomonas 81 
aeruginosa (PA). It was hypothesized that 1) rats with SP or PA pneumonia can be discriminated from 82 
uninfected controls; and 2) the different pathogens can be distinguished using exhaled breath analysis.  83 
 84 
Methods 85 
The study was approved by the Animal Welfare Body at the AMC Amsterdam, the Netherlands (project 86 
number LEICA125AD-1).  87 
 88 
Experimental groups 89 
Male adult specific pathogen-free Sprague-Dawley rats (n=50) weighing ~350 grams (Envigo, 90 
Netherlands) received an intra-tracheal inoculation of either: 1) a total of   ̴1x107 colony forming units 91 
(CFU) of SP (ATCC 6303; Rockville, USA) (n=18); or 2) a total of  ̴1x107CFU of PA (PA103; Iglewski 92 
Laboratory, USA) (n=16), under light anaesthesia using isoflurane 3%; or 3) 200µL saline (n=16) for the 93 
control group. 94 
 95 
Anaesthesia and mechanical ventilation 96 
24 hours post-inoculation, an anaesthetic mixture (0.15mL/100g body weight)  of 1.8mL ketamine 97 
(100mg/mL; Eurovet Animal Health, Netherlands), 0.5mL dexmedetomidine (0.5mg/mL; Vetoquinol, 98 
Netherlands), 0.2mL atropine (0.5mg/mL; Eurovet Animal Health) and 0.5mL NaCl 0.9% was injected. The 99 
rats were weighed, tracheotomised and connected to a mechanical ventilator (Dräger, Netherlands). The 100 
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rats were pressure controlled ventilated with 16cmH2O over 2cmH2O positive end-expiratory pressure, 101 
using a fraction of inspired oxygen of 32%.  102 
 103 
Exhaled breath collection 104 
For breath sampling, a stainless steel tube filled with sorbent material (for GC-MS: TenaxTM GR 60/80; 105 
Interscience, Netherlands; and for SIFT-MS Carbograph 1TD/Carbopack X; Markes International, UK) was 106 
inserted between the expiratory ventilator tubing and a pump (Markes). For 10 minutes VOCs were 107 
absorbed onto the steel sorbent tube with a flow of 100mL/min. The sorbent tubes were stored at 4°C 108 
for a maximum of 14 days until analysis. 109 
 110 
Other samples 111 
Directly after collection of the exhaled breath samples, the rats were sacrificed. For the bronchoalveolar 112 
lavage (BAL) sample, three 2mL aliquots of saline were instilled and directly withdrawn from the right 113 
lung. The upper lobe of the left lung was fixed in 4% buffered formaldehyde for later paraffin 114 
embedding, sectioning and staining at the pathology department. The middle and lower lobes of the left 115 
lung were homogenized.  116 
 117 
Thermal desorption gas chromatography–mass spectrometry  118 
Sorbent tubes were placed within a TD unit (TD100; Markes) and heated (250°C for 15min, flow 119 
30mL/min). The VOCs were captured on a cold trap (5°C), which was rapidly heated to 300°C for 1min, 120 
after which the molecules were splitless injected through a transfer line at 120°C onto an Inertcap 121 
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5MS/Sil GC column (30m, diameter 0.25mm, film thickness 1μm, 1,4-bis(dimethylsiloxy)phenylene 122 
dimethyl polysiloxane; Restek, Netherlands) at 1.2mL/min. The oven temperature was isothermal at 40°C 123 
for 5min, then increased to 270° at 10°C/min and kept isothermal at 270°C for 5min.  124 
Molecules were ionized using electron ionization (70eV), and the fragment ions were detected 125 
using a quadrupole mass spectrometer (GCMS-GP2010; Shimadzu, Netherlands) with a scan range of 37–126 
300Da. Ion fragment peaks were used for statistical analysis. The predictive fragment ions were manually 127 
checked in the raw chromatograms and corresponding metabolites were tentatively identified using 128 
National Institute of Standards and Technology library (NIST, Gaithersburg, USA); we followed the 129 
Metabolomics Standards Initiative for metabolite identification(26).  130 
 131 
Thermal desorption selected ion flow tube–mass spectrometry 132 
The discriminatory power of the GC-MS and SIFT-MS full-scan VOC patterns was compared. SIFT-MS 133 
(Voice200; Syft Technologies) was used as an off-line instrument in combination with a TD unit (UNITY; 134 
Markes). A full scan was performed in the mass-to-charge (m/z) ratio of 15+ to 200+, without the 135 
limitation of changing VOC levels throughout breathing manoeuvres, as would be the case when 136 
analysing on-line. Sorbent tubes were placed in an autosampler (ULTRA; Markes) connected to the TD 137 
unit. TD was performed in tube conditioning mode and the tubes were heated to 270°C (flow 30mL/min) 138 
for 10min. The VOCs were recollected in a 1L Tedlar® gas sampling bag (Sigma-Aldrich) at the split outlet. 139 
The Tedlar® bag was placed at the sample inlet of the SIFT-MS (Voice200; Syft Technologies, New 140 
Zealand) and full scan was initiated with a scan range from m/z 15+ to 200+ for 3 precursor ions (H3O+, 141 
NO+, O2+), a dwell time of 100ms, a count limit of 10000 and 8 repeats. Raw data in counts/second of all 142 
scanned ions were corrected for the instrument calibration function (ICF) of the measurement day. The 143 
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ion counts were multiplied by the ion-specific instrument calibration function. The ICF-corrected data 144 
were then used for statistical analysis. 145 
 146 
Infection assessment 147 
Serial 10-fold dilutions of the homogenized lung and the BAL fluid were plated on blood agar plates and 148 
incubated overnight at 37°C. The number of CFUs were counted the next morning. Cell counts in the 149 
BALF were measured (Z2 Coulter Particle Counter; Beckman Coulter Corporation, USA) and neutrophils 150 
counted (CytospinTM 4 Cytocentrifuge; Thermo ScientificTM, USA).  151 
Histologic examination of the 4µm hematoxylin and eosin-stained lung sections was performed 152 
by a pathologist blind to group identity. Lung inflammation and damage was determined using a lung 153 
infection scoring system as described previously(4). 154 
 155 
Data analysis 156 
All statistical analyses were performed in R statistics through the R-studio interface(22). A p-value ≤0.05 157 
was considered statistically significant for single comparisons. P-values were corrected for multiple-158 
testing by Benjamini-Hochberg correction(2). Diagnostic accuracy was measured by the area under the 159 
receiving operating characteristics curve (AUROCC).  160 
The allocation of an animal to pneumonia or control group was the primary dependent variable. 161 
All analyses were repeated for SP vs. control, PA vs. control and SP vs. PA, to study the inter-pathogen 162 
variance. The VOCs measured by TD GC-MS and SIFT-MS were used as 2 separate predictor matrices for 163 
pneumonia status.  164 
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First, high dimensional datasets with VOCs were reduced by principal component (PC) analysis. 165 
The first 6 PCs were retained, capturing 57% of variance. A conservative number of PCs was used 166 
because of the relatively low number of animals. Mann-Whitney U test was used to test differences in 167 
PCs between groups. PCs with a p-value ≤0.1 were used for logistic regression (LR) analysis(14). Second, 168 
individual VOCs were compared using the “limma” package and p-values and fold changes were reported 169 
and shown in a volcano plot. VOCs with an adjusted p-value ≤0.05 were identified. Third, sparse partial 170 
least square discriminant analysis (sPLS-DA; MixOmics package) with leave-one-out cross-validation was 171 
used to identify the most discriminatory VOCs and estimate the accuracy of such a selected dataset.  We 172 
could not use bootstrap analyses due to low sample number so we employed leave-one-out where data 173 
from an individual animal was left out of the modelling. The correct classification rate (CCR) was 174 
calculated by comparing the AUROCC of the leave-one-out cross-validated model to a similarly 175 
constructed model for 1000 randomly permutated labels, as is recommended(27).  176 
 177 
Results 178 
All animals survived the 24h post-inoculation and the 1-hour period of mechanical ventilation. Median 179 
BALF white cell count was (in cells/mL) 13.8x105 (IQR: 8.7x105–16.7x105) for the SP rats, 5.9x105 (IQR: 180 
4.0x105–11.2x105) for the PA rats and 1.3x105 (IQR: 1.2x105–1.5x105) for the control rats (p<0.001). The 181 
CFU counts of the BALF samples differed significantly between the groups: no CFUs were seen on the 182 
agar plates for BALF of the PA and control rats, compared to a median of 4.8x106 (IQR: 1.2–8.8 x106) 183 
CFU/mL for the SP animals (p<0.001). Only the homogenate of the SP group showed significant growth 184 
(p<0.001; 1.0x109 (IQR: 7.4–1.0 x109) CFU/mL), compared to 650 (IQR: 0–4.4x103) CFU/mL for the PA rats 185 
and 0 (IQR: 0–1.4^103) CFU/mL for the controls. Microscopic counts of the percentages of neutrophils 186 
present on the stained cytospin preparations differed between groups (p<0.001), with a median of 88.5 187 
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(IQR: 72.5–95.3) for the SP animals, 81 (IQR: 68.5–89) for the PA group and 2.5 (IQR: 0–5) for the 188 
controls.  189 
The percentage of pneumonia on histopathological investigation was significantly higher in the 190 
SP rats (p<0.001). Pneumonia scores were significantly higher in the infected vs. the non-infected 191 
animals: median pneumonia score was 8 (IQR: 6–10.5) for the SP rats and 5.5 (IQR: 3–6.5) for the PA rats, 192 
compared to 3 (IQR: 2–4) for the controls (p<0.001).  193 
 194 
TD GC-MS 195 
The analysis of significant PCs (using PCs 1, 4 and 5) and subsequent LR model for infected vs. non-196 
infected animals showed an AUROCC of 0.93 (95%-CI: 0.85–1). The AUROCC (using PC 1, 4 and 5) was 197 
0.93 (95%-CI: 0.84–1) for SP vs. controls, 0.98 (95%-CI: 0.94–1) for PA vs. controls using PC 4 and 5, and 198 
0.99 (95%-CI: 0.97–1) for SP vs. PA using PC 1, 3 and 5. 199 
Figure 1 shows the group comparisons. Comparing infected vs. non-infected animals, 16% of 200 
VOCs were significantly different between groups, resulting in a false discovery rate (FDR) of 31.3%. For 201 
SP vs. controls the significant rate was 30% (FDR 16%), for PA vs. Controls 15% (FDR 33%) and for SP vs. 202 
PA 42% (FDR 12%). Table 1 shows identified VOCs, with an adjusted p-value of <0.05 to limit chances of 203 
false discovery.  204 
sPLSDA with leave-one-out cross-validation at the animal level followed by LR showed an 205 
AUROCC of 0.85 (95%-CI: 0.73–0.96) for infected vs. non-infected animals, with a correct classification 206 
rate (CCR) of 94.6%  (Figure 2a). SP vs. controls had an AUROCC of 0.92 (95%-CI: 0.83–1) (CCR 98.1%), PA 207 
vs. controls an AUROCC of 0.97 (95%-CI: 0.92–1) (CCR 99.9%), and SP vs. PA an AUROCC of 0.98 (95%-CI: 208 
0.94–1) (CCR 99.9%)(Figure 3a).  209 
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 210 
TD SIFT-MS 211 
The analyses were repeated for the SIFT-MS data. For infected vs. non-infected animals the significant 212 
PCs (PC 1 and 4) had an AUROCC of 0.78 (95%-CI: 0.62–0.94). For SP vs. controls the AUROCC (using PC 1, 213 
2 and 4) was 0.82 (95%-CI: 0.67–0.96), for PA vs. controls the AUROCC was 0.85 (95%-CI: 0.69–1) using 214 
PC 4, and for the SP vs. PA animals the AUROCC was 1.0 (95%-CI: 1–1) using PC 1 and 2. 215 
Aforementioned method for sPLSDA analysis resulted in an AUROCC of 0.54 (95%-CI: 0.38–0.71) 216 
for infected vs. non-infected animals (Figure 2b) (CCR 1.6%), an AUROCC of 0.63 (95%-CI: 0.43–0.83) (CCR 217 
26.9%) for SP vs. controls, an AUROCC of 0.79 (95%-CI: 0.62–0.96) (CCR 77.6%) for PA vs. controls, and an 218 
AUROCC of 0.89 (95%-CI: 0.77–1) (CCR 19.6%) for SP vs. PA (Figure 3b).   219 
 220 
Discussion 221 
The exhaled breath of rats with SP or PA pneumonia can be discriminated from uninfected controls with 222 
good accuracy using GC-MS. The discriminative accuracy was even higher for the discrimination between 223 
the two specific pathogens. Overall, GC-MS results provided better results than SIFT-MS as analytical 224 
platform for this purpose. 225 
This is the first study that demonstrates an evidently better discriminative performance of 226 
breath analysis when used for discrimination between pathogens instead of distinguishing healthy from 227 
diseased. So far, clinical studies have been aiming to show a potential for breath analysis to diagnose a 228 
variety of lung diseases, e.g. ARDS(10) and COPD(3). Clinical studies investigating breathomics for the 229 
diagnosis of respiratory infection, showed a general focus on the identification of distinctive individual 230 
VOCs or breathprints to be served as biomarkers for pneumonia(12, 20, 24), and not specifically for the 231 
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causative pathogens. In contrast, our results demonstrate that breath analysis can differentiate bacteria 232 
with a higher diagnostic accuracy. In retrospect, this finding seems to be more in line with the available 233 
in-vitro data. A meta-analysis of all available studies linked more VOCs to one or a few pathogens and 234 
rarely found VOCs in the headspace of all studies(8).   235 
 Among the identified VOCs were several alkane hydrocarbons (Table 1). Alkanes are associated 236 
with oxidative stress(16), yet have been linked to pneumonia as well(19). The abundance of octane may 237 
be secondary to peroxidation of oleic acid(16). The other identified hydrocarbons – hexadecane 238 
(previously linked to lung infection(28)), 2-,4-dimethylhexane, 2-methylnonane and 2-,4-239 
dimethylheptane (previously associated with S. aureus and E. coli infection(11)) – were mainly produced 240 
by SP. 2-Propanol is – as endogenous compound – suggested to be a product of an enzyme mediated 241 
reduction of acetone(25) and, like octane, might serve as a possible biomarker(7). Tetrachloroethylene is 242 
used primarily in the dry cleaning industry and likely to be a contaminant. 2-Propenoic acid is known to 243 
derive from ventilator and tubing(7). Table 1 shows that presently many of our discovered VOCs could 244 
not be named and remained unidentified, which does not limit them to be of value, for their specific 245 
combination of retention time and mass spectrum enables future recognition of these markers in clinical 246 
studies and therefore they might still serve as markers for the presence of a specific bacterium. 247 
Animal models provide a controlled environment free of genetic or behavioural influences, 248 
allowing selected pathogens to be studied without coexisting microorganisms or diseases contaminating 249 
the breath signal. Several studies in murine models focused on the differentiation between individual 250 
pathogens by detecting selective VOC patterns(29, 30). Since the present study used GC-MS, individual 251 
VOCs could be identified as opposed to the recognition of patterns. These VOCs could serve as specific 252 
markers for particular pathogens and could thus be applied for future human exhaled breath studies(21). 253 
However, the diagnostic accuracy of single markers provides less accuracy than composite signals. 254 
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Pathogen identification by VOC analysis in exhaled breath may be most feasible by breathprint analysis 255 
and not solely by the analysis of one or several specific VOCs.    256 
A strength of this study is the controlled environment of the established animal model, using a 257 
breath sampling technique that had been proven successful in rat experiments(9). Genetically identical 258 
rats were used and a precisely regulated amount of bacteria was inoculated. Another strength is the use 259 
of two independent analytical platforms that showed similar trends in results. Limitations of the study 260 
were the small panel of pathogenic bacteria that was studied and the relatively limited amount of 261 
animals that was used. Due to the small number of animals used in these experiments, cross-validation 262 
had to be performed at the leave-one-animal-out level. Another limitation is the number of VOCs of 263 
interest that remained unidentified.  264 
To date, GC-MS is seen as the gold standard for exhaled breath analysis(8). SIFT-MS has the 265 
advantage of being quick (few minutes), without requiring calibration standards for the measured VOCs. 266 
Furthermore it can be used as an on-line instrument enabling real-time measurements, without the need 267 
of sample preconcentration. However, an off-line approach was used in the current study, involving a 268 
rather novel variation of coupling a TD unit upfront the instrument, as earlier described for detection of 269 
selected compounds in ambient air(23). In this off-line confirmation, full scan mode is more feasible: a 270 
chosen range of ions with defined m/z ratio can be scanned for a chosen time, without the limitation of 271 
on-line sampling, including changing VOC levels throughout breathing manoeuvres. An additional 272 
advantage of using SIFT-MS off-line in combination with the TD unit is the possibility to preconcentrate 273 
and potentially measure trace elements in exhaled breath which would fall below the detection limit 274 
without preconcentration. 275 
 In the present study, both the GC-MS and the SIFT-MS technique delivered adequate accuracies 276 
regarding the ability of VOCs to differentiate between causative pathogens, but only GC-MS could 277 
Downloaded from www.physiology.org/journal/ajplung at UVA Universiteitsbibliotheek SZ (145.117.227.011) on February 14, 2019.
 14
discriminate between infected and non-infected rats. GC-MS data for infected vs. non-infected animals 278 
could have been over-fit, as indicated by the high FDRs in the univariate analysis. Nevertheless, GC-MS 279 
results have proved superior to SIFT-MS results before in gaseous samples containing large numbers of 280 
VOCs at high concentrations(15). 281 
In conclusion, the current focus of exhaled breath metabolomics might have to be reconsidered: 282 
in addition to the aim to detect the general presence of respiratory infection, clinical studies should 283 
concentrate more on the discrimination between pathogens.  284 
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Figure legends 290 
 291 
 292 
Figure 1. Volcano plots for the group comparisons. 293 
 294 
 295 
Figure 2. SPLSDA analysis with leave-one-out cross-validation: infected (purple triangles: SP; purple dots: 296 
PA) vs. non-infected (green rhombus) animals: 2a. (left); GC-MS results; 2b. (right): SIFT-MS results. 297 
 298 
Figure 3. SPLSDA analysis with leave-one-out cross-validation: SP (red triangles) vs. PA (blue dots) 299 
animals: 3a. (left); GC-MS results; 3b. (right): SIFT-MS results. 300 
  301 




1.  Bean HD, Jimenez-Diaz J, Zhu J, Hill JE. Breathprints of model murine bacterial lung infections are 304 
linked with immune response. Eur Respir J 45: 181–190, 2015. 305 
2.  Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach 306 
to multiple testing. J R Stat Soc B 57: 289–300, 1995. 307 
3.  Van Berkel JJBN, Dallinga JW, Moller GM, Godschalk RWL, Moonen EJ, Wouters EFM, Van 308 
Schooten FJ. A profile of volatile organic compounds in breath discriminates COPD patients from 309 
controls. Respir Med 104: 557–563, 2010. 310 
4.  Beurskens CJP, Aslami H, Kuipers MT, Horn J, Vroom MB, Van Kuilenburg ABP, Roelofs JJTH, 311 
Schultz MJ, Juffermans NP. Induced hypothermia is protective in a rat model of pneumococcal 312 
pneumonia associated with increased adenosine triphosphate availability and turnover. Crit Care 313 
Med 40: 919–926, 2012. 314 
5.  Boots  a W, Smolinska A, van Berkel JJBN, Stobberingh EE, Boumans MLL, Moonen M, Wouters 315 
EFM, Dallinga JW, Schooten FJ Van. Identification of microorganisms based on gas 316 
chromatography-mass spectrometric analysis of volatile organic compounds in headspace gases. J 317 
Biomed Biotechnol 8: 1752, 2014. 318 
6.  Boots AW, van Berkel JJBN, Dallinga JW, Smolinska A, Wouters EF, van Schooten FJ. The 319 
versatile use of exhaled volatile organic compounds in human health and disease. J Breath Res 6: 320 
027108, 2012. 321 
7.  Bos L, Schultz M, Sterk P. A simple breath sampling method in intubated and mechanically 322 
ventilated critically ill patients [Online]. Respir Physiol Neurobiol 191: 67–74, 2014. 323 
Downloaded from www.physiology.org/journal/ajplung at UVA Universiteitsbibliotheek SZ (145.117.227.011) on February 14, 2019.
 17
http://www.sciencedirect.com/science/article/pii/S1569904813003674#. 324 
8.  Bos LDJ, Sterk PJ, Schultz MJ. Volatile Metabolites of Pathogens: A Systematic Review. PLoS 325 
Pathog 9: e1003311, 2013. 326 
9.  Bos LDJ, van Walree IC, Kolk AHJ, Janssen H-G, Sterk PJ, Schultz MJ. Alterations in exhaled breath 327 
metabolite-mixtures in two rat models of lipopolysaccharide-induced lung injury. J Appl Physiol 328 
115, 2013. 329 
10.  Bos LDJ, Weda H, Wang Y, Knobel HH, Nijsen TME, Vink TJ, Zwinderman AH, Sterk PJ, Schultz 330 
MJ. Exhaled breath metabolomics as a noninvasive diagnostic tool for acute respiratory distress 331 
syndrome. Eur Respir J 44: 188–197, 2014. 332 
11.  Filipiak W, Beer R, Sponring A, Filipiak A, Ager C, Schiefecker A, Lanthaler S, Helbok R, Nagl M, 333 
Troppmair J, Amann A. Breath analysis for in vivo detection of pathogens related to ventilator-334 
associated pneumonia in intensive care patients: a prospective pilot study. J Breath Res 9: 335 
016004, 2015. 336 
12.  Fowler SJ, Basanta-Sanchez M, Xu Y, Goodacre R, Dark PM. Surveillance for lower airway 337 
pathogens in mechanically ventilated patients by metabolomic analysis of exhaled breath: a case-338 
control study. Thorax (2015). doi: 10.1136/thoraxjnl-2014-206273. 339 
13.  Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE. Diagnosis of ventilator-associated 340 
pneumonia: Controversies and working toward a gold standard. Curr Opin Infect Dis 26: 140–150, 341 
2013. 342 
14.  Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, Fowler SJ. Non-invasive 343 
phenotyping using exhaled volatile organic compounds in asthma. Thorax 66: 804–809, 2011. 344 
Downloaded from www.physiology.org/journal/ajplung at UVA Universiteitsbibliotheek SZ (145.117.227.011) on February 14, 2019.
 18
15.  Langford VS, Graves I, McEwan MJ. Rapid monitoring of volatile organic compounds: A 345 
comparison between gas chromatography/mass spectrometry and selected ion flow tube mass 346 
spectrometry. Rapid Commun Mass Spectrom 28: 10–18, 2014. 347 
16.  Lawal O, Knobel H, Weda H, Bos LD, Nijsen TME, Goodacre R, Fowler SJ. Volatile organic 348 
compound signature from co-culture of lung epithelial cell line with Pseudomonas aeruginosa. 349 
Analyst (2018). doi: 10.1039/c8an00759d. 350 
17.  Lawal O, Muhamadali H, Ahmed WM, White IR, Nijsen TME, Goodacre R, Fowler SJ. Headspace 351 
volatile organic compounds from bacteria implicated in ventilator-associated pneumonia 352 
analysed by TD-GC/MS. J Breath Res 12: 26002, 2018. 353 
18.  Metwaly S, Cote A, Donnelly SJ, Banoei MM, Winston BW. Evolution of ARDS biomarkers, will 354 
metabolomics be the answer? Am J Physiol Lung Cell Mol Physiol : 526–534, 2018. 355 
19.  Van Oort PM, Povoa P, Schnabel R, Dark P, Artigas A, Bergmans D, Felton T, Coelho L, Schultz 356 
MJ, Fowler SJ, Bos LD. The potential role of exhaled breath analysis in the diagnostic process of 357 
pneumonia – a systematic review. J Breath Res 12: 24001, 2018. 358 
20.  Oort PMP Van, Bruin S De, Weda H, Knobel HH, Schultz MJ, Bos LD. Exhaled Breath 359 
Metabolomics for the Diagnosis of Pneumonia in Intubated and Mechanically-Ventilated Intensive 360 
Care Unit ( ICU ) -Patients. Int J Mol Sci 18: 1–14, 2017. 361 
21.  van Oort PMP, Nijsen T, Weda H, Knobel H, Dark P, Felton T, Rattray NJW, Lawal O, Ahmed W, 362 
Portsmouth C, Sterk PJ, Schultz MJ, Zakharkina T, Artigas A, Povoa P, Martin-Loeches I, Fowler 363 
SJ, Bos LDJ. BreathDx – molecular analysis of exhaled breath as a diagnostic test for ventilator–364 
associated pneumonia: protocol for a European multicentre observational study. BMC Pulm Med 365 
17: 1, 2017. 366 
Downloaded from www.physiology.org/journal/ajplung at UVA Universiteitsbibliotheek SZ (145.117.227.011) on February 14, 2019.
 19
22.  R Development Core Team. R: A language and environment for statistical computing. Vienna, 367 
Austria: R Foundation for Statistical Computing [Online]. 2010. http://www.r-project.org. 368 
23.  Ross BM, Vermeulen N. The combined use of thermal desorption and selected ion flow tube 369 
mass spectrometry for the quantification of xylene and toluene in air. Rapid Commun Mass 370 
Spectrom 21: 3608–3612, 2007. 371 
24.  Schnabel R, Fijten R, Smolinska A, Dallinga J, Boumans M-L, Stobberingh E, Boots A, Roekaerts 372 
P, Bergmans D, van Schooten FJ. Analysis of volatile organic compounds in exhaled breath to 373 
diagnose ventilator-associated pneumonia. Sci Rep 5: 17179, 2015. 374 
25.  Schubert JK, Miekisch W. Breath Analysis in Critically Ill Patients—Potential and Limitations. 375 
Volatile Biomarkers (2013). doi: 10.1016/B978-0-44-462613-4.00009-X. 376 
26.  Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, Fan TW-M, Fiehn O, Goodacre 377 
R, Griffin JL, Hankemeier T, Hardy N, Harnly J. Proposed minimum reporting standards for 378 
chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Inititative 379 
(MSI). Metabolomics 3: 211–221, 2007. 380 
27.  Westerhuis JA, Hoefsloot HCJ, Smit S, Vis DJ, Smilde AK, Velzen EJJ, Duijnhoven JPM, Dorsten 381 
FA. Assessment of PLSDA cross validation. Metabolomics 4: 81–89, 2008. 382 
28.  Zhou Y, Chen E, Wu X, Hu Y, Ge H, Xu P, Zou Y, Jin J, Wang P, Ying K. Rational lung tissue and 383 
animal models for rapid breath tests to determine pneumonia and pathogens. Am J Transl Res 9: 384 
5116–5126, 2017. 385 
29.  Zhu J, Bean HD, Jimenez-Diaz J, Hill JE. Secondary electrospray ionization-mass spectrometry 386 
(SESI-MS) breathprinting of multiple bacterial lung pathogens, a mouse model study. J Appl 387 
Physiol 114: 1544–1549, 2013. 388 
Downloaded from www.physiology.org/journal/ajplung at UVA Universiteitsbibliotheek SZ (145.117.227.011) on February 14, 2019.
 20
30.  Zhu J, Jimenez-Diaz J, Bean HD, Daphtary NA, Aliyeva MI, Lundblad LKA, Hill JE. Robust detection 389 
of P. aeruginosa and S. aureus acute lung infections by secondary electrospray ionization-mass 390 
spectrometry (SESI-MS) breathprinting: from initial infection to clearance. J Breath Res 7: 37106, 391 
2013. 392 
 393 
Downloaded from www.physiology.org/journal/ajplung at UVA Universiteitsbibliotheek SZ (145.117.227.011) on February 14, 2019.
Downloaded from www.physiology.org/journal/ajplung at UVA Universiteitsbibliotheek SZ (145.117.227.011) on February 14, 2019.
Downloaded from www.physiology.org/journal/ajplung at UVA Universiteitsbibliotheek SZ (145.117.227.011) on February 14, 2019.
Downloaded from www.physiology.org/journal/ajplung at UVA Universiteitsbibliotheek SZ (145.117.227.011) on February 14, 2019.
Table 1 
Group comparison VOC 
Infected vs. non-infected  Octane, 4-methyl- 
  Octane, 2-5-dimethyl 
  Unidentified naphthalene compound 
  Unidentified cyclic compound 
  Unidentified 
  Unidentified branched aldehyde 
  Tetra chloroethylene 
  Unidentified cyclic compound 
SP vs. control Octane, 4-methyl- 
  Octane, 2-5-dimethyl 
  Unidentified naphthalene compound 
  Unidentified 
  Unidentified cyclic compound 
  Hexadecane 
  Unidentified  
  Unidentified  
  Hexane, 2-,4-dimethyl- 
  2-Propanol, 1-methyloxy- 
  Nonane, 2-methyl- 
  Heptane, 2-,4-dimethyl 
  Unidentified cyclic compound 
  Unidentified 
PA vs. control  Unidentified branched aldehyde 
  2-propenoic acid, 2-ethylhexyl ester 
  Unidentified cyclic compound 
 
Table 1. Identified VOCs with an adjusted p-value of <0.05, per comparison. In bold: identical VOCs 
showing overlap between the group comparisons. 
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